XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Net revenues $ 15,878 $ 16,659 $ 16,887
Cost of sales 8,284 8,933 9,351
Gross profit 7,594 7,726 7,537
Research and development expenses, net 967 997 1,010
Selling and marketing expenses 2,429 2,498 2,614
General and administrative expenses 1,099 1,173 1,192
Intangible assets impairments 424 1,502 1,639
Goodwill impairment 0 4,628 0
Other asset impairments, restructuring and other items 341 479 423
Legal settlements and loss contingencies 717 60 1,178
Other income (98) (40) (76)
Operating (loss) income 1,716 (3,572) (443)
Financial expenses—net 1,058 834 822
Income (loss) before income taxes 658 (4,406) (1,265)
Income taxes (benefit) 211 (168) (278)
Share in (profits) losses of associated companies—net (9) (138) 13
Net income (loss) 456 (4,099) (1,000)
Net income (loss) attributable to non-controlling interests 39 (109) (2)
Net income (loss) attributable to Teva $ 417 $ (3,990) $ (999)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ 0.38 $ (3.64) $ (0.91)
Diluted $ 0.38 $ (3.64) $ (0.91)
Weighted average number of shares (in millions):      
Basic 1,102 1,095 1,091
Diluted 1,107 1,095 1,091